CrossrefInfokarte
Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review
Acta Haematologica Polonica · 2026-10-29 · 57 (5) · 380-389
DOI: 10.5603/ahp.112557 ↗Abstract
Kein Abstract verfügbar.
EUVIMED